 |
 |
Thanks for clearing this up Ray. I had a mind full of questions after reading the related article. Regards, Nic 56/14 On Tue, Feb 17, 2009 at 11:30 PM, rayilynlee <[log in to unmask]> wrote: > You should know that Dennis Turner, the sole trial subject, had this > treatment in 1999, with a DBS. When I called him on 3-24-06 he told me his > PD had returned with a vengeance. There is no current communication from > Turner as to his present condition. > > The FDA never approved of Phase II and I can only guess that because it was > done with DBS it is impossible to tell what accounted for his temporary > improvement. Patricia Payne of MA was touted by the Family Research Council > and David Prentice as an ASC "success" because she was going to be in Phase > II, but Phase II never happened. > > I suspect that nothing has changed since 2006 except for the peer review > and they are dragging this case out again to get FDA approval and $. Also > the assaults against embryonic stem cell research have intensified as Obama > gets ready to issue executive orders to overturn the Bush restrictions. > > I did not post this article because of these omissions. > > Ray > > Rayilyn Brown > Director AZNPF > Arizona Chapter National Parkinson Foundation > [log in to unmask] > > -------------------------------------------------- > From: "schild.m" <[log in to unmask]> > Sent: Tuesday, February 17, 2009 3:16 AM > To: <[log in to unmask]> > Subject: Autologous Neural Stem Cells to Treat Parkinson's > > Groundbreaking Paper Publishes Long Term Results of a Successful Phase I >> Clinical Trial Using Autologous Neural Stem Cells to Treat Parkinson's >> Disease >> >> Last update: 9:11 a.m. EST Feb. 16, 2009 >> LOS ANGELES, Feb 16, 2009 /PRNewswire via COMTEX/ -- Scientists announced >> today the publication of a landmark peer-reviewed paper in the February >> issue >> of the Bentham Open Stem Cell Journal which outlines the long term results >> of >> the world's first clinical trial using autologous neural stem cells for >> the >> treatment of Parkinson's disease. According to lead author, Michel F. >> Levesque, MD, FRCS(C), FACS, "We have documented the first successful >> adult >> neural stem cell transplantation to reverse the effects of Parkinson's >> disease and demonstrated the long term safety and therapeutic effects of >> this >> approach." Dr Levesque is a principal investigator for NeuroGeneration, a >> biotechnology company, and is affiliated with the UCLA School of Medicine >> and >> the Brain Research Institute. >> The researcher reports that the publication of the article, "Therapeutic >> Microinjection of Autologous Adult Human Neural Stem Cells and >> Differentiated >> Neurons for Parkinson's Disease: Five-Year Post-Operative Outcome" in the >> Bentham Open Stem Cell Journal heralds an important moment in regenerative >> and personalized medicine. "Our paper describes how we were able to >> isolate >> patient-derived neural stem cells, multiply them in vitro and ultimately >> differentiate them to produce mature neurons before they are reintroduced >> into the brain's basal ganglia. This is performed without the patient >> requiring immunosuppressants. Of particular note are the striking results >> this study yielded -- for the five years following the procedure the >> patient's motor scales improved by over 80% for at least 36 months. A word >> of >> caution must be added however, since this is a single case study, a larger >> clinical trial is needed to replicate these findings," says Levesque. >> "We have been pioneering the use of neural stem cells for >> neurodegenerative >> disorders since 1998 and were the first research team to successfully use >> differentiated adult neural stem cells for the cellular restoration and >> treatment of Parkinson's disease. Our original methodology is based on the >> replication of several steps in human neurogenesis to regenerate millions >> of >> mature neurons characterized before transplantation. These steps are >> essential to establish safety, efficacy and to understand mechanisms of >> brain >> repair. The autologous approach mitigates the long term risks associated >> with >> allogenic transplants, including infection, inflammatory response, immune >> rejection, and poor biologic efficacy. In addition, we believe it was the >> combination of dopaminergic and GABA-ergic neurons that produced the long- >> lasting motor improvement. This suggests that in humans, Parkinson's >> disease >> is more than a chronic dopaminergic dysfunction and involves the >> GABA-ergic >> system with its glial environment. The relevance of this discovery cannot >> be >> understated because it questions the classical dopaminergic model of >> Parkinson's disease," says Levesque. >> Scientists at NeuroGeneration are planning a larger prospective clinical >> trial for Parkinson's disease. "It's our hope that this trial will result >> in >> the launch of a cost-effective and lasting therapies for the millions of >> patients suffering from debilitating neurodegenerative disorders," >> concludes >> Levesque. >> ABOUT NEUROGENERATION: >> NeuroGeneration, a biotechnology company, is engaged in the development of >> biological products for the repair of neurological disorders. The company >> has >> completed a Phase I clinical trial for Parkinson's disease using adult >> derived neural stem cells. It intends to start a Phase II study for the >> treatment of Parkinson's disease as soon as it received final approval >> from >> the FDA. It is also planning Phase I studies for multiple systems atrophy, >> atypical parkinsonism, stroke, spinal cord and brain injuries, and >> Alzheimer's disease. The company was founded in 1998 and is headquartered >> in >> Los Angeles, California. >> FOR MORE INFORMATION CONTACT: >> Heather Larrabee >> NeuroGeneration >> 310.659.3880 >> [log in to unmask] >> http://www.neurogeneration.com >> >> ---------------------------------------------------------------------- >> To sign-off Parkinsn send a message to: mailto: >> [log in to unmask] >> In the body of the message put: signoff parkinsn >> > > ---------------------------------------------------------------------- > To sign-off Parkinsn send a message to: mailto: > [log in to unmask] > In the body of the message put: signoff parkinsn > ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn